Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
4.895
-0.055 (-1.11%)
Apr 29, 2025, 11:28 AM EDT - Market open
Monte Rosa Therapeutics Revenue
In the year 2024, Monte Rosa Therapeutics had annual revenue of $75.62M. Monte Rosa Therapeutics had revenue of $60.65M in the quarter ending December 31, 2024.
Revenue (ttm)
$75.62M
Revenue Growth
n/a
P/S Ratio
4.84
Revenue / Employee
$564,343
Employees
134
Market Cap
301.09M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
GLUE News
- 1 day ago - Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer - GlobeNewsWire
- 5 weeks ago - Monte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs - GlobeNewsWire
- 7 weeks ago - Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025 - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 2 months ago - Bullish On Monte Rosa Therapeutics' 'Undruggable' Targets With QuEEN - Seeking Alpha
- 4 months ago - Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 months ago - Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors - GlobeNewsWire